SCHEMBL14760719

SCHEMBL14760719

Cc1cc2c(F)c(Nc3ccnc(Nc4cccc(C=CC(=O)N5CCOCC5)c4)n3)ccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.41
KDR P35968 1/20 0.41
EPHB4 P54760 3/20 0.40
SYK P43405 1/20 0.39
MAPK8 P45983 3/20 0.38
AURKA O14965 2/20 0.38
EGFR P00533 1/20 0.38
JAK2 O60674 2/20 0.38
JAK3 P52333 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ERBB2 P04626 1/20 0.37
CDK2 P24941 2/20 0.37
CDK9 P50750 2/20 0.37
DAPK3 O43293 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14024613 1.00 BTK (0.41) BTKKDREPHB4SYKMAPK8
SCHEMBL14760598 0.86 KDR (0.58) BTKKDRSYKMEN1NPC1
SCHEMBL14024695 0.86 KDR (0.58) BTKKDRSYKMEN1NPC1
SCHEMBL14760574 0.85 KDR (0.45) BTKKDREPHB4SYKMAPK8
SCHEMBL14024645 0.85 KDR (0.45) BTKKDREPHB4SYKMAPK8
SCHEMBL14024619 0.80 ERBB2 (0.54) BTKKDREPHB4SYKJAK2
SCHEMBL14024652 0.79 AURKA (0.55) SYKMAPK8AURKACLK2GSK3A
SCHEMBL14024658 0.78 AURKA (0.47) KDREPHB4SYKAURKAJAK2
SCHEMBL14024592 0.77 SYK (0.51) BTKKDRSYKEGFRERBB2
SCHEMBL14024626 0.77 KDR (0.49) BTKKDREPHB4SYKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901143-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2014-12-02 US disclosed
EP-2154967-B9 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-07-23 EP disclosed
EP-2154967-B1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-03-05 EP disclosed
US-20130065890-A1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTERPRISES LIMITED 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065890-A1 PYRIMIDINE DERIVATIVES TYMS, KDR, FLT4 BTK 1723/4885KDR 2/4885EPHB4 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.